Rheumatoid Arthritis Vaccine trials begin
In the next five years, thanks to scientists from the UK, a vaccine based on the patient's own cells for the treatment of rheumatoid arthritis may appear. A team of researchers from the University of Newcastle (Newcastle University), as reported by the media of the United Kingdom, plans to launch a pilot study of the vaccine with the participation of 8 patients with rheumatoid arthritis.
Such technologies are already undergoing clinical trials in patients with cancer, but they will be tested for the first time in rheumatoid arthritis. John John Isaacs, professor of clinical rheumatology at the University, a leading researcher, noted that the work has only just begun, but the experimental stage was very impressive. According to him, scientists expect that the vaccine will be able to specifically suppress the pathological autoimmune response.
Professor Alan Silman, medical director of the charity fund "Arthritis Research Campaign", which finances the research project, noted that the cost of one dose of the vaccine will reach 25 thousand pounds. But since its appearance is associated with the ability to stop the development of the disease, even such a cost does not seem too high, notes The Daily Telegraph.
Portal "Eternal youth" www.vechnayamolodost.ru02.09.2008